1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Kinnate Zeroes In On BRAF Subpopulation For Exarafenib Development Strategy

BeiGene And Partners Present RAF Dimer Inhibitor Data

 
• By Alaric DeArment

Kinnate presented early monotherapy and combination data for its pan-RAF inhibitor at AACR, but its prioritization of BRAF Class II drew analyst concerns that its focus might be too narrow.

Kinnate presented Phase I data for its pan-RAF inhibitor, exarafenib • Source: Shutterstock

Kinnate Biopharma, Inc. is putting the bulk of its initial energy into certain patients with non-small cell lung cancer (NSCLC) and melanoma in developing the pan-RAF inhibitor exarafenib as a monotherapy, while at least initially putting less of an emphasis on other patient populations, a strategy that drew concern from an analyst that it would narrow the drug’s market opportunity.

The company presented early data from its Phase I study of exarafenib at the American Association for Cancer Research meeting on 17 April, including both monotherapy data as well as data for the drug in combination with Pfizer Inc.’s MEK inhibitor, Mektovi (binimetinib)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.